All News #Library
Others
Gesynta Doses First Patient In Vipoglanstat Endometriosis Trial
17 Mar 2026 //
PR NEWSWIRE
Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
27 Apr 2022 //
PHARMAFILE
Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
26 Apr 2022 //
PHARMAFILE
Gesynta Pharma announces development program for its drug candidate GS-248
14 Jun 2021 //
CISION
Gesynta Pharma initiates Phase II study
28 Jan 2021 //
PRESS RELEASE

Market Place
Sourcing Support